MedWatch

ALK has decent growth forecast in sight

Danish bank Sydbank deems that allergy company ALK's tablet sales are well underway, but will keep eye on Covid-19 consequences in Wednesday's interim report from the company.

Photo: ALK / PR/peter

Danish allergy company ALK's Q4 report will probably show growing tables sales with emphasis on the firm's 2021 guidance and expectations for future growth.

"We expect that ALK will present a revenue growth forecast at around 8-12 percent. Speaking in local currency and operating result in the interval DKK 350-450m (USD 56.8-73.1m)," writes Søren Løntoft Hansen, analyst at Danish bank Sydbank.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs